- Point of care molecular diagnostics enable rapid, accurate detection of diseases at or near the patient site, playing a critical role in improving healthcare outcomes in both clinical and remote settings
- The market growth is driven by the increasing prevalence of infectious diseases, rising demand for timely diagnosis, and technological advancements in molecular testing platforms that offer portability, ease of use, and faster results
- North America dominates the point of care molecular diagnostics market with the largest revenue share of 38.5% in 2024, supported by advanced healthcare infrastructure, significant R&D investments, and widespread adoption in hospitals and clinics. The U.S. leads this growth with increasing deployment of molecular diagnostic devices for diseases such as COVID-19, cancer, and genetic disorders
- Asia-Pacific is expected to be the fastest-growing region in the point of care molecular diagnostics market during the forecast period, propelled by improving healthcare access, growing government initiatives for disease control, and rising awareness of early diagnosis in countries such as China, India, and Japan
- The respiratory diseases segment is projected to dominate the market with a significant share of 42.3% in 2024, due to the high demand for rapid and accurate diagnosis of conditions such as COVID-19, influenza, and tuberculosis, which require timely intervention to reduce transmission and improve patient outcomes
